A Randomized, Double-blind, Placebo-controlled Trial of Augmentation With an Extended Release Formulation of Methylphenidate in Outpatients With Treatment-Resistant Depression

Abstract

We examined the efficacy and tolerability of augmentation with an extended release formulation of methylphenidate (OROS MPH, Concerta) in patients with major depression who were nonresponders or partial responders to antidepressants. Sixty subjects with treatment-resistant depression (TRD) participated in a 4-week, randomized, double-blind, placebo-controlled study of augmentation with methylphenidate (18-54 mg/d). The preexisting antidepressant dose was unchanged. The primary efficacy measure was change in the 21-item Hamilton Depression Rating Scale from randomization to end of treatment. Data were analyzed with intent-to-treat with last observation carried forward approach. There were no statistically significant differences between the methylphenidate (n = 30) and placebo (n = 30) groups in reduction in 21-item Hamilton Depression Rating Scale scores (drug, -6.9; placebo, -4.7) from baseline to end of treatment (F1,47 = 1.24, P = 0.22), although responders were numerically higher in the extended-release methylphenidate group (40.0%) than in the placebo group (23.3%). On the secondary efficacy measures of changes in Clinical Global Impression-Improvement and Severity scores and Beck Depression Inventory-Second Edition, the drug failed to separate from placebo, although the proportion of responders in the drug group were numerically higher than placebo. There were no significant differences in weight, heart rate, and blood pressure changes between the 2 groups. The common adverse events were loss of appetite, nausea, headache, and anxiety. The mean dose of drug was 34.2 mg/d. The study did not demonstrate a statistically significant benefit for augmentation with methylphenidate in TRD. Combination of methylphenidate with antidepressants was well tolerated. Adequately powered, randomized, controlled trials are necessary to fully evaluate the efficacy of extended-release methylphenidate in TRD.

Fatigue Syndrome in Sarcoidosis

“…It has been also used as an adjunctive therapy of depression [45,46]. Another neurostimulant, modafinil is a dopamine re-uptake inhibitor used in the treatment of narcolepsy.…”

Adult ADHD and comorbid depression: A consensus-derived diagnostic algorithm for ADHD

“…Psychostimulants have been used as an augmentation strategy for treatment-resistant depression though with limited evidence for success. 74,75 The panel recommends if ADHD is the primary disabling condition and associated with mild depression, the ADHD should be treated fi rst. As mentioned previously, ADHD is often accompanied by distress, demoralization or mild depressive symptoms.…”

Beyond ADHD and narcolepsy: psychostimulants in general psychiatry

“…(Postolache 1999;Patkar 2006). Patkar and colleagues (2006) noted that in 60 out-patients with treatment-resistant depression, more participants responded to extended-release methylphenidate compared with placebo (40% v. 23.3%).…”